Systems biology of personalized medicine

Bioinformatics for Systems Biology

Volumn 9781597454407, Issue , 2009, Pages 615-630

  Webb, Craig Paul ^a   Cherba, David Michael ^a  

^a VAN ANDEL INSTITUTE   (United States)

Author keywords

Biomarkers; Cancer; Individualized therapy; Informatics; Pharmacogenomics; Systems Biology

Indexed keywords

BIOLOGY; DIAGNOSIS;

CANCER; INDIVIDUALIZED THERAPY; INFORMATICS; PHARMACOGENOMICS; SYSTEMS BIOLOGY;

BIOMARKERS;

EID: 77952524739     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-440-7_32     Document Type: Chapter

References (64)

1. Stumpf MP, Kelly WP, Thorne T, Wiuf C. Evolution at the system level: the natural history of protein interaction networks. Trends Ecol Evol 2007;22(7):366-373.
2. Huang S. Back to the biology in Systems Biology: what can we learn from biomolecular networks? Brief Funct Genomic Proteomic 2004;2(4):279-297.
3. van der Greef J, Martin S, Juhasz P, et al. The art and practice of Systems Biology in medicine: mapping patterns of relationships. J Proteome Res 2007;6(4):1540-1559.
4. Fujarewicz K, Kimmel M, Lipniacki T, Swierniak A. Adjoint systems for models of cell signaling pathways and their application to parameter fitting. IEEE/ACM transactions on computational biology and bioinformatics/IEEE, ACM 2007;4(3):322-335.
5. Wang E, Lenferink A, O'Connor-McCourt M. Cancer Systems Biology: exploring cancer-associated genes on cellular networks. Cell Mol Life Sci 2007;64(14):1752-1762.
6. Hanahan D, Weinberg RA. The hallmarks of cancer. In: Cell; 2000:57-70.
7. Webb CP, Vande Woude GF. Genes that regulate metastasis and angiogenesis. J Neurooncol 2000;50(1-2):71-87.
8. Aranda-Anzaldo A. Cancer development and progression: a non-adaptive process driven by genetic drift. Acta Biotheor 2001;49(2):89-108.
9. Balakrishnan A, Bleeker FE, Lamba S, et al. Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res 2007;67(8):3545-50.
10. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314(5797):268-274.
11. Maron BJ, Hauser RG. Perspectives on the failure of pharmaceutical and medical device industries to fully protect public health interests. Am J Cardiol 2007;100(1):147-151.
12. Goodsaid F, Frueh FW. Implementing the U. S. FDA guidance onpharmacogenomic data submissions. Environ Mol Mutagen 2007;48(5):354-358.
13. Jain KK. Challenges of drug discovery for personalized medicine. Curr Opin Mol Ther 2006;8(6):487-492.
14. Nusbaum R, Isaacs C. Management updates for women with a BRCA1 or BRCA2 mutation. Mol Diagn Ther 2007;11(3):133-44.
15. Daly AK. Individualized drug therapy. Curr Opin Drug Discov Devel 2007;10(1):29-36.
16. deLeon J, Susce MT, Murray-Carmichael E. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool. Mol Diagn Ther 2006;10(3):135-151.
17. Marsh S. Impact of pharmacogenomics on clinical practice in oncology. Mol Diagn Ther 2007;11(2):79-82.
18. Duffy MJ. Role of tumor markers in patients with solid cancers: A critical review. Eur J Intern Med 2007;18(3):175-184.
19. Thompson IM, Ankerst DP. Prostate-specific antigen in the early detection of prostate cancer. Cmaj 2007;176(13):1853-1858.
20. Webb CP, Pass HI. Translation research: from accurate diagnosis to appropriate treatment. J Transl Med 2004;2(1):35.
21. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005;353(15):1564-1573.
22. Miller LD, Liu ET. Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine. Breast Cancer Res 2007;9(2):206.
23. Kaklamani VG, Gradishar WJ. Gene expression in breast cancer. Curr Treat Options Oncol 2006;7(2):123-128.
24. Canales RD, Luo Y, Willey JC, et al. Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol 2006;24(9):1115-1122.
25. Rhodes DR, Kalyana-Sundaram S, Tomlins SA, et al. Molecular concepts analyzes links tumors, pathways, mechanisms, and drugs. Neoplasia 2007;9(5):443-454.
26. O'Donovan N, Crown J. EGFR and HER-2 antagonists in breast cancer. Anticancer Res 2007;27(3 A):1285-1294.
27. Tsuda H. HER-2 (c-erbB-2) test update: present status and problems. Breast Cancer 2006;13(3):236-248.
28. Hochhaus A, Erben P, Ernst T, Mueller MC. Resistance to targeted therapy in chronic myelogenous leukemia. Semin Hematol 2007;44(1 Suppl 1):S15-24.
29. Bublil EM, Yarden Y. The EGF receptor family: spearheadingamerger of signaling and therapeutics. Curr Opin Cell Biol 2007;19(2):124-134.
30. Wen L, Li W, Sobel M, Feng JA. Computational exploration of the activated pathways associated with DNA damage response in breast cancer. Proteins 2006;65(1):103-110.
31. Schafer R, Schramme A, Tchernitsa OI, Sers C. Oncogenic signaling pathways and deregulated target genes. Recent Results Cancer Res 2007;176:7-24.
32. Lin J, Gan CM, Zhang X, et al. A multidimensional analyzes of genes mutated in breast and colorectal cancers. Genome Res 2007;17(9):1304-1318.
33. Lassere MN, Johnson KR, Boers M, et al. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol 2007;34(3):607-615.
34. Burczynski ME, Dorner AJ. Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies. Pharmacogenomics 2006;7(2):187-202.
35. Floyd E, McShane TM. Development and use of biomarkers in oncology drug development. Toxicol Pathol 2004;32 Suppl 1:106-115.
36. Kelloff GJ, Sigman CC. New science-based endpoints to accelerate oncology drug development. Eur J Cancer 2005;41(4):491-501.
37. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006;6(11):835-845.
38. Graul AI. Promoting, improving and accelerating the drug development and approval processes. Drug news & perspectives 2007;20(1):45-55.
39. Goutsias J, Lee NH. Computational and experimental approaches for modeling gene regulatory networks. Curr Pharm Des 2007;13(14):1415-1436.
40. Kuick R, Misek DE, Monsma DJ, et al. Discovery of cancer biomarkers through the use of mouse models. Cancer Lett 2007;249(1):40-48.
41. Logue LJ. Genetic testing coverage and reimbursement: a provider's dilemma. Clin Leadersh Manag Rev 2003;17(6):346-350.
42. Roberts TG, Jr., Chabner BA. Beyond fast track for drug approvals. N Engl J Med 2004;351(5):501-555.
43. Swanson BN. Delivery of high-quality biomarker assays. Dis Markers 2002;18(2):47-56.
44. Caldwell JS. Cancer cell-based genomic and small molecule screens. Adv Cancer Res 2007;96:145-173.
45. Watters JW, Roberts CJ. Developing gene expression signatures of pathway deregulationin tumors. Mol Cancer Ther 2006;5(10):2444-2449.
46. Michor F, Nowak MA, Iwasa Y. Evolution of resistance to cancer therapy. Curr Pharm Des 2006;12(3):261-271.
47. Sarkaria JN, Yang L, Grogan PT, et al. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther 2007;6(3):1167-1174.
48. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007;25(5):587-595.
49. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 2006;7(8):1041-1053.
50. Gossage L, Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 2007;33(6):565-577.
51. Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proceedings of the National Academy of Sciences of the United States of America 2007;104(32):13086-13091.
52. Shtiegman K, Kochupurakkal BS, Zwang Y, et al. Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene 2007;26(49):6968-6978.
53. Weinstein IB, Joe AK. Mechanisms of disease: Oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006;3(8):448-457.
54. Schulenburg A, Ulrich-Pur H, Thurnher D, et al. Neoplastic stem cells: a novel therapeutic target in clinical oncology. Cancer 2006;107(10):2512-2520.
55. Huang S. Back to the biology in Systems Biology: what can we learn from biomolecular networks? Briefings in functional genomics & proteomics 2004;2(4):279-297.
56. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science (New York, NY 2006;314(5797):268-274.
57. Rhodes DR, Kalyana-Sundaram S, Tomlins SA, et al. Molecular concepts analyzes links tumors, pathways, mechanisms, and drugs. Neoplasia (New York, NY 2007;9(5):443-454.
58. Michor F, Nowak MA, Iwasa Y. Evolution of resistance to cancer therapy. Current pharmaceutical design 2006;12(3):261-271.
59. Weinstein IB, Joe AK. Mechanisms of disease: Oncogene addiction-a rationale for molecular targeting in cancer therapy. Nature clinical practice 2006;3(8):448-457.
60. www.fda.gov/cber/gdlns/iche15term.htm
61. www.fda.gov/bbs/topics/news/2006/NEW01337.html
62. www.fda.gov/cdrh/oivd/guidance/1610.html
63. www.xbtransmed.com
64. www.genego.com